FUEL UTILIZATION CLINICAL AND MOLECULAR PROGNOSTIC FACTORS GENOMIC VULNERABILITIES
Posterior location of pancreas, in close proximity to duodenum, common bile duct, celiac plexus, superior mesenteric artery (SMA), and portal vein, leads to late diagnosis as well as very bothersome symptoms of obstruction of biliary drainage, with infection, pain, and unresectability. Genetically engineered mouse models (e.g., the KPC model by Hingorani et al., 2005) Primary patient-derived tumor xenografts (e.g., the PancXenoBank by Jimeno et al., 2009) BREAKING TOLERANCE Anti-CTLA-4
Anti-PD1
Anti-PD-L1 
Hypermethylation

Inhibitors of DNMTs
Stem cell hypothesis CD44, CD24, and epithelial-specific antigen (ESA) positive (Li et al., 2007) Possible total time to evolve: 21-28 years Exact cell of origin not clear (candidates include epithelium, acinar cell, islet cell)
11.7 years: original gene mutation -> primary cancer 6.8 years primary -> metastasis 2.7 years appearance of metastases -> death. No extra-pancreatic disease Pancreatic cancer can basically be divided into two major subtypes: adenocarcinoma, which is thought to arise in the exocrine portion of the pancreas (95% of cases), and rare endocrine tumors, which arise from islet cells (often designated as neuroendocrine tumors). This Snapshot concentrates on the most common and lethal type of adenocarcinoma of the pancreas: infiltrating ductal adenocarcinoma (designated here as pancreatic ductal adenocarcinoma or PDA). Pancreatic cancer kills more than 37,000 people each year in the United States and more than 213,000 people worldwide. It has the worst 1 and 5 year survival rates of all cancers and, unfortunately, it is increasing in incidence. The highest rates of pancreatic cancer incidence are seen in industrialized and Western countries. In Europe, Nordic countries have the highest incidence rates (perhaps suggesting a role for Vitamin D). In the United States, the incidence is particularly high in Native Hawaiians, African Americans, and Korean Americans. The incidence of pancreatic cancer also increases sharply after age 50. Pancreatic cancer in young patients is frequently familial; there is a 40% increase in risk for pancreatic cancer if there is familial pancreatitis. Other risk factors include diabetes, metabolic syndrome, pancreatitis, cigarette smoking, heavy alcohol consumption, infectious agents (H. pylori, hepatitis B), and gastric resection. Diets low in fruits and vegetables and involving high intake of meat (particularly barbequed) are also associated with increased risk.
This Snapshot is designed to outline the pathology of PDA, its association with inherited cancer syndromes, information regarding the origin and evolution of the disease, clinical and molecular prognostic factors, and clinical staging along with common treatment regimens that have been proven to increase survival. Clearly, new ways to attack pancreatic cancer are needed. Also outlined in the SnapShot are four possible ways to attack the disease via genomic vulnerabilities, PDA's fuel utilization pathways, stroma targets, and breaking immune tolerance. These include some already discovered targets as well as some additional therapeutic possibilities. We hope that this cataloging of possibilities alongside the clinical aspects of the disease will help drive new approaches and ideas for development of new therapies and new methods for early detection of this awful disease.
